Articles related to GLYCEMIC CONTROL

Whether prescribing them for diabetes or weight loss, what factors should you consider when choosing among the seven approved GLP-1 agonist formulations? This concise review highlights the variables.

The results of these trials show that vitamin D reduced the risk of diabetes progression by 3% to 18% after three years, with serum 25-hydroxy D levels of at least 125 nmol/L showing the greatest benefit. Vitamin D was also associated with a 30% increase in the likelihood of returning to normal glucose regulation.

This summary of a January 2023 JACC article highlights the study finding that rosuvastatin was “vastly superior to… any of the six supplements studied in the trial.” The study compared rosuvastatin to cinnamon, garlic, turmeric, red yeast rice, fish oil, and plant sterols. Rosuvastatin yielded a reduction in cholesterol of nearly 38 percent in just 28 days. The supplements had little to no effect but were significantly more costly than the statin.

Versus placebo, pemafibrate yielded a more than 25% greater reduction in triglycerides, VLDL, remnant cholesterol, and apolipoprotein C-III in patients with type 2 diabetes. However, there was no reduction versus placebo in MI, ischemic stroke, need for coronary revascularization, or CV death.

The statin group experienced an average LDL-C reduction of 37.9%, according to the results of the single-center, prospective, randomized, single-blind SPORT study (Supplements, Placebo, or Rosuvastatin), while those who took dietary supplements experienced LDL-C changes similar to those in the placebo group. Additionally, rosuvastatin-treated patients experienced average decreases in triglycerides of 19% and total cholesterol of 24%. For any of the supplements, there were no differences in either total cholesterol or triglycerides when compared to placebo.

Among more than 200 adolescents 12 to 18 years of age over a 68-week period, nearly 75% of those in the treatment group experienced weight loss of > 5%, compared with only about 15% of those with placebo plus lifestyle intervention. GI adverse events were more common in the treatment group.